Profound Medical Corp

Profound Medical Corp

7.34
USD
-0.08
(-1.08%)
-0.93EPS
212.44MMarket Cap
Mar 11Next Earn
Profound Medical Corp
NASDAQ:PROF
(Nasdaq Stock Market)

Recent

price

7.34

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
0.51
0.14
0.38
0.42
0.34
0.32
0.34
0.43
0.53
0.68
Revenue per Share
-32.6
-3.6
-2.93
-1.94
-1.11
-1.37
-1.25
-1.5
-1.38
-1.34
-1.12
-1.41
-0.93
Basic EPS, GAAP
-11.68
-1.55
-2.79
-1.58
-0.98
-1.37
-1.21
-1.12
-1.24
-1.07
-0.95
-1.27
-0.9
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
5.35
1.84
2
1.22
1.33
1.21
4.82
3.88
2.49
1.46
2.01
1.83
1.16
Book Value per Share
5.22
1.84
1.96
0.48
0.96
0.79
4.59
3.68
2.46
1.44
2
1.83
1.16
Tangible Book Value per Share
- -
2
4
6
10
11
17
20
21
21
25
30
35
Basic Weighted Avg Shares
- -
- -
- -
3
1
4
7
7
7
7
11
16
24
Sales/Revenue/Turnover
- -
- -
- -
-359.49
-776.04
-357.07
-258.26
-440.72
-443.08
-397.99
-309.57
-256.27
-145.08
Operating Margin (%)
- -
- -
- -
1
1
2
2
2
2
1
1
1
- -
Depreciation Expense
-7
-9
-12
-12
-11
-15
-22
-31
-29
-28
-28
-43
-32
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-383.77
-797.88
-364.69
-296.03
-446.66
-429.11
-393.43
-260.45
-264.44
-137.51
Profit Margin (%)
1
10
13
4
16
15
93
73
58
36
63
70
43
Working Capital
2
3
3
- -
6
7
1
1
7
6
3
4
3
LT Debt
1
7
11
9
14
14
97
81
52
31
60
66
43
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-201.86
-132.67
-119.18
-96.02
-106.06
-38.71
-34.5
-43.23
-68.06
-60.7
-67.12
-87.04
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
5
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
37
37
Market Capitalization
235
243
212

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
70
59
55
Cash, Cash Equivalents & STI
50
38
33
Accounts Receivable, Net
9
10
12
Inventories
9
10
10
Total Current Liabilities
11
9
12
Payables & Accruals
3
2
3
ST Debt
5
5
5
Deferred Revenue
- -
- -
1

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
68.15%
2.16%
9.95%
Free Cash Flow
37.15%
15.48%
63.94%
Net Income, GAAP
19.79%
17.08%
53.04%
Sales/Revenue/Turnover
- -
19.63%
50.73%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
2
3
4
11
2025
3
2
5
6
16
2026
5
2
10
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.27
-0.28
-0.38
-0.21
-1.12
2025
-0.36
-0.52
-0.26
-0.27
-1.41
2026
-0.19
-0.26
-0.21
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) develops and commercializes customizable, incision-free therapies that combine real-time magnetic resonance imaging, thermal ultrasound, robotically-driven ablation and closed-loop temperature feedback control for the radiation-free treatment of diseased tissue, primarily targeting prostate conditions and uterine fibroids; its lead product, TULSA-PRO, provides transurethral ultrasound ablation for localized prostate cancer, radio-recurrent prostate cancer, benign prostatic hyperplasia and palliation in advanced cases, offering customizable whole-gland or partial ablation while preserving functional abilities such as urinary continence and sexual function, with CE mark, Health Canada approval and U.S. FDA 510(k) clearance; it also markets Sonalleve, a MR-HIFU platform for non-invasive treatment of uterine fibroids and bone metastases pain palliation, approved by the China FDA for fibroids and under exploration for abdominal cancers and hyperthermia applications. Founded in 2008 and headquartered in Mississauga, Ontario, Canada, the company operates globally with key commercial activities in North America, Europe and Asia Pacific, serving urologists, oncologists and interventional radiologists through direct sales, partnerships and distribution networks. Recent developments include an exclusive distribution and supply agreement with Getz Healthcare in November 2025 to commercialize TULSA-PRO in Australia and New Zealand, regaining exclusive Canadian distribution rights from Knight Therapeutic via a one-time payment in November 2025, and a strategic partnership between Texas Prostate and Dallas Medical Center to launch a TULSA program expanding Medicare access in the U.S.

Company News

  • Profound Medical to Participate in the Stifel 2026 Healthcare Conference

  • What Profound Medical (PROF) Said on Its Q3 Earnings Call

  • Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth

  • Profound Medical (PROF) Expected to Beat Earnings Estimates: Should You Buy?

  • Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade

  • Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth

  • Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let's Huddle' Webinar

  • Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?

  • TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity

  • Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?

  • Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

  • Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue

  • Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference

  • Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President

  • Profound's Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days'

  • Profound Medical Announces Management Change

  • Profound Medical Launches ‘Let's Huddle', a Global Community Supporting Men Throughout Their Prostate Care Journey

  • Profound Medical Q2 Earnings Call Highlights

  • Profound Medical (PROF) Q2 Earnings Surpass Estimates

  • Profound Medical Reports Second Quarter 2026 Financial Results